| Date | Title | Description |
| 01.07.2026 | GrowthCap Announces The Top Women Leaders in Growth Investing of 2026 | GrowthCap is pleased to announce The Top Women Leaders in Growth Investing of 2026
NEW YORK, July 1, 2026 /PRNewswire-PRWeb/ -- Behind many of the most successful growth investment firms, portfolio companies, and value creation strategies a... |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., ... |
| 21.07.2025 | CurTec: Acquisition By Ampersand Capital Partners | Ampersand Capital Partners, a private equity firm focused on growth equity investments in life sciences and healthcare, has acquired CurTec, a Netherlands-based manufacturer of high-performance plastic packaging for pharmaceutical and speci... |
| 21.04.2025 | Lexington Medical Receives Growth Investment from Ampersand Capital Partners | Lexington Medical, a Bedford, MA-based leader in minimally-invasive surgical stapling solutions, received a strategic investment from Ampersand Capital Partners.
The company intends to use the funds for accelerated growth in product innovat... |
| 13.02.2025 | GrowthCap Announces The Top Growth Equity Firms of 2024 | It is our distinct pleasure to announce this year's Top Growth Equity Firms.
NEW YORK, Feb. 13, 2025 /PRNewswire-PRWeb/ -- For over a decade, we have studied growth equity firms. Undeniably, the trait that the best firms share is a culture ... |
| 09.12.2024 | The Rise of Earth Imagery and Automated Analytics: A New Era in Technology | In the fast-paced world of technology, two companies are making waves. Spexi and Abselion are harnessing innovation to reshape industries. They recently secured significant funding, propelling their missions forward. Spexi, based in Vancouv... |
| 09.12.2024 | VIVEbiotech Receives Investment from Ampersand Capital Partners | VIVEbiotech, a San Sebastian, Spain-based lentiviral vector contract development and manufacturing organization (CDMO), received a growth equity investment from Ampersand Capital Partners.
The amount of the deal was not disclosed. As part o... |
| 09.12.2024 | Spexi Raises $11.5M in Series A Funding | Spexi, a Vancouver, Canada-based earth imagery company, raised $11.5M in Series A funding.
The round was led by Blockchange Ventures.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Bill Lak... |
| 21.08.2024 | GrowthCap Announces The Top Private Equity Firms of 2024 | GrowthCap is pleased to announce The Top Private Equity Firms of 2024.
NEW YORK, Aug. 21, 2024 /PRNewswire-PRWeb/ -- GrowthCap is pleased to announce The Top Private Equity Firms of 2024. Since 2013, we have been gathering information on gr... |
| 09.08.2024 | Phosphorex Welcomes NOF CORPORATION as Shareholder and Strategic Partner | HOPKINTON, Mass. and TOKYO, Aug. 9, 2024 /PRNewswire/ -- Phosphorex, a drug delivery-focused contract development and manufacturing organization ("CDMO") backed by Boston-based private equity firm Ampersand Capital Partners, annou... |
| 09.07.2024 | Phosphorex Appoints John Rigg to Board of Directors | HOPKINTON, Mass., July 9, 2024 /PRNewswire/ -- Phosphorex, a drug delivery-focused contract development and manufacturing organization ("CDMO"), is pleased to announce the appointment of John Rigg to its Board of Directors. Mr. Ri... |
| 01.07.2024 | Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA | Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world.
BOSTON and INDIANAPOLIS, July 1, 2024 /PRNewswire/ -- Genezen, a best-in-class... |
| 04.04.2023 | iuvo BioScience Hires Industry Executive to Lead Commercial Organization | Sanjeev will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth.
ROCHESTER, N.Y. (PRWEB... |
| 18.10.2022 | AcuraBio Appoints Talented Senior Executives to Drive Global Growth Program | BRISBANE, AUS, Oct 18, 2022 - (ACN Newswire) - AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, recently acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, announced today new senior exe... |
| 02.06.2022 | Dynamk Capital Co-Leads $21M Vernal Biosciences round along with Ampersand Capital Partners
Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth |
COLCHESTER, Vt., June 2, 2022 /PRNewswire/ -- Vernal Biosciences, a technology-leading mRNA manufacturer and formulator of LNP-mRNA, announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solut... |
| 20.11.2020 | Ampersand Capital Partners raises $670m fund to buy out trio of assets from existing PE vehicles | Healthcare-focused Ampersand Capital Partners has raised $670m for a continuation vehicle to buy up a trio of portfolio |
| 21.10.2020 | StageBio Expands Its Global Presence With Acquisition of TPL Path Labs | |
| 07.11.2019 | StageBio Merges with Alizée Pathology | StageBio has merged with Alizée Pathology to form the leading provider of specialized histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio w... |
| 18.06.2019 | Ampersand Capital Partners Recaps N2 Biomedical | N2 Biomedical, a leading provider of coating and surface treatment solutions to the medical device industry, announced today the majority recapitalization of the company by Ampersand Capital Partners. As part of the transaction N2 also anno... |
| 30.05.2019 | Ampersand Acquires Vibalogics | Vibalogics GmbH, a contract development and manufacturing organization (CDMO) focused on complex live biological products, is being acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in t... |
| 11.12.2018 | Ampersand backs Merger of Histo-Scientific Research Labs and Vet Path Services | Histo-Scientific Research Laboratories, Inc. (HSRL), has completed its merger with Vet Path Services (VPS) to create the leading provider of research and pre-clinical histology, pathology and archiving services for the biopharmaceutical, me... |
| 19.11.2018 | Ampersand Capital Partners Acquires Pacific Biomarkers and Merges Company with NEOMED-LABS | Ampersand Capital Partners announced today that it has completed the acquisition of Pacific Biomarkers and merged it with existing portfolio company NEOMED-LABS. This merger brings together two leading bioanalytical CROs with unrivaled cred... |
| 05.11.2018 | Ampersand-backed DeTech Acquires ETP | Detector Technology, Inc., a leader in analytical instrument contract design and manufacturing, with its roots in mass spectrometry, announced the acquisition of industry-leading electron multiplier manufacturer ETP Ion Detect Pty Ltd, base... |
| 05.11.2018 | Ampersand-backed DeTech Acquires ETP | Detector Technology, Inc., a leader in analytical instrument contract design and manufacturing, with its roots in mass spectrometry, announced the acquisition of industry-leading electron multiplier manufacturer ETP Ion Detect Pty Ltd, base... |
| 05.09.2018 | Ampersand Acquires NEOMED-LABS | Ampersand Capital Partners, together with the management team of NEOMED-LABS and the NEOMED Institute, announced today that Ampersand has partnered with management in the acquisition of NEOMED-LABS from its not-for-profit founder and parent... |
| 05.09.2018 | Ampersand Acquires NEOMED-LABS | Ampersand Capital Partners, together with the management team of NEOMED-LABS and the NEOMED Institute, announced today that Ampersand has partnered with management in the acquisition of NEOMED-LABS from its not-for-profit founder and parent... |
| 26.03.2018 | MedPharm Receives Investment from Ampersand Capital Partners | MedPharm, a Guilford, UK-based developer of topical and transdermal products for drug developers, received an investment from Ampersand Capital Partners.
The amount of the deal was not disclosed.
The company will use the funds to expand its... |
| 26.03.2018 | Ampersand Invests in MedPharm | MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to announce an investment by Ampersand Capital Partners.
Since its founding almost 20 years ago, MedPharm ... |
| 26.03.2018 | Ampersand Invests in MedPharm | MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to announce an investment by Ampersand Capital Partners.
Since its founding almost 20 years ago, MedPharm ... |
| 20.03.2018 | Term Sheet — Tuesday, March 20 | FERRO OUT
Good morning, Term Sheet readers. Lots of news today.
Paid Content You can't secure what you can't see From ExtraHop
Some people on Twitter were skeptical about the sudden retirement, asking “What’s the rest of the story?”
Hours l... |
| 20.03.2018 | Ampersand Invests in Nexcelom Bioscience | Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will... |
| 19.03.2018 | Ampersand Raises $450M | Ampersand Capital Partners is pleased to announce the closing of the firm’s latest fund, Ampersand 2018 Limited Partnership, with $450 million in limited partner commitments. This fund, which is Ampersand’s ninth fund since 1992, was signif... |
| 20.02.2018 | Ampersand-backed Detector Technology Acquires Scientific Instrument Services | Detector Technology, Inc., a leader in analytical instrument contract design and manufacturing, with a focus on mass spectrometry and sample preparation, today announced the acquisition of long-time partner Scientific Instrument Services. T... |
| 11.02.2018 | Ampersand-backed Confluent Acquires Corpus Medical | FREMONT, Calif.–(BUSINESS WIRE)–Confluent Medical Technologies, a global leader in medical device contract manufacturing, today completed the acquisition of Corpus Medical. Confluent Medical is a contract manufacturer with full scale capabi... |
| 23.01.2018 | Ampersand-backed Avista Pharma Acquires Solid Form Solutions | DURHAM, N.C.–(BUSINESS WIRE)–Avista Pharma Solutions, Inc. announced today that it has completed the acquisition of Solid Form Solutions, Ltd. located in Edinburgh, Scotland. Solid Form Solutions is a leading provider of solid state chemist... |
| 04.01.2018 | Detector Technology Secures Growth Equity Investment from Ampersand Capital Partners | Detector Technology, Inc., a leader in analytical instrument contract design and manufacturing, with a focus on mass spectrometry products, today announced an equity investment by Ampersand Capital Partners, a private equity firm with a foc... |
| 12.12.2017 | LakePharma Raises Growth Capital from Summit Partners and Ampersand Capital Partners | LakePharma, a leading U.S. biologics company specializing in antibody and protein engineering, cell line development and protein production, announced today that it has raised $30 million in growth financing led by global growth equity inve... |
| 27.11.2017 | Ampersand-backed Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts | Brammer Bio, a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO), today announced the completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufactur... |
| 10.08.2017 | Ampersand Announces Exit of Roadrunner Pharmacy | Ampersand Capital Partners announced today that portfolio company Roadrunner Pharmacy has been acquired by Vets First Choice. In 2012, Ampersand invested in a partial recapitalization that was Roadrunner's first and only institutional equit... |
| 07.03.2017 | Ampersand and 1315 Capital Closes Buy of Genoptix | An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not being di... |
| 07.03.2017 | Ampersand Capital Partners and 1315 Capital to Acquire Genoptix from Novartis | The management team led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc., a Carlsbad, California-based provider of testing solutions in hematology and soli... |
| 07.03.2017 | Ampersand and 1315 Capital Closes Buy of Genoptix | An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not being di... |
| 02.02.2017 | Ampersand Completes Growth Equity Investment In Corpus Medical | Corpus Medical, Inc., a Silicon Valley-based contract development and manufacturing organization focused on interventional medical devices, catheter-based delivery systems and implants, announced today that it has completed a majority recap... |
| 19.09.2016 | Frank Witney Joins Ampersand as Operating Partner | Ampersand Capital Partners, a healthcare-focused, middle market private equity firm, is pleased to announce the addition of Frank Witney, PhD, as an Operating Partner. Dr. Witney is actively working with Ampersand's investment team to ident... |
| 19.11.2015 | Florida Biologix Receives Financing from Ampersand Capital Partners | Florida Biologix, an Alachua, FL-based contract development and manufacturing organization (CDMO) focused on complex biological products, received financial backing from Ampersand Capital Partners.
The investment will be used to further exp... |
| 30.07.2015 | Protein Technologies Receives Equity and Debt Funding | Protein Technologies, Inc., a Tucson, Arizona-based provider of peptide synthesis instruments, received an equity investment and a credit facility of undisclosed amount.
Ampersand Capital Partners made the investment while Square 1 Bank pro... |
| 07.01.2015 | CutisPharma Raises Venture Capital and Debt Funding | CutisPharma, a Wilmington, Mass.-based developer of “value-added kits” for the compounding pharmacy market, raised an undisclosed amount of venture capital and debt funding.
Ampersand Capital Partners made the investment while Silicon Valle... |
| 04.01.2014 | NutraMed Receives $12.5M Credit Facility from Square 1 Bank; Equity Investment from Ampersand Capital Partners | NutraMed,Inc., a Chino, California-based manufacturer of nutraceuticals and dietary supplements, recieved a $12.5m credit facility from Square 1 Bank.
The company intends to use the proceeds for acquisition financing and working capital.
Fo... |
| 08.05.2013 | Why one former life sciences VC wouldn’t recommend a career in venture capital (video) | He spent nearly two decades in venture capital, but in a conversation with me about the current state of life sciences investing, he said he wouldn’t necessarily recommend it to anyone as a career nowadays. “Generally, on an early stage ven... |
| 28.03.2012 | 5 trends in oil & gas technology, and why you should care | Oil is in the news again. Last week, oil prices touched all-time highs due to Iranian export declines; the chief economist of the International Energy Agency said that high oil prices could cause an international recession. And whereas it l... |
| - | Why one former life sciences VC wouldn’t recommend a career in venture capital (video) | Life as a venture capitalist isn’t always as glamorous as some people think it is. It’s also not something that necessarily comes naturally.
“I learned the venture business over 10 years; it’s truly an apprenticeship business,” said Peter P... |
| - | Ampersand Capital Partners | “Accelerating Growth with Healthcare Entrepreneurs. We're Ampersand Capital Partners. A Boston-based private equity firm with more than 25 years of experience.” |
| - | ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business | BAUDETTE, Minn.--(BUSINESS WIRE)--Mar 9, 2021--
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharm... |
